Roman Fabbricatore

Articles

CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer

June 3rd 2025

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.

SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

June 3rd 2025

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC

June 2nd 2025

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

Talquetamab Is Safe and Effective in R/R Multiple Myeloma

June 1st 2025

Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.

Glofitamab/GemOx Enhances OS and PFS vs Rituximab in R/R DLBCL

June 1st 2025

Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.

Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma

June 1st 2025

The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.

Zanubrutinib Plus Venetoclax Yields High Response Rates in Treatment-Naive CLL/SLL

May 31st 2025

Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC

May 31st 2025

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Prospective, Real-World Study Highlights Feasibility of Outpatient Robotic Partial Nephrectomy in Renal Tumors

April 29th 2025

A high proportion of patients with renal tumors were discharged on the same day after receiving robotic partial nephrectomy.

Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies

April 11th 2025

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

March 18th 2025

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer

March 17th 2025

Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.

Avutometinib With Defactinib Exceeds Response Threshold in Advanced Mesonephric Gynecologic Cancer

March 16th 2025

The combination of avutometinib and defactinib has previously shown activity in patients with low-grade serous ovarian cancer.

Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC

February 18th 2025

Neoadjuvant chemotherapy and concurrent chemoradiation could represent a safe, effective bladder-sparing approach in MIBC.

Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC

February 15th 2025

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer

February 13th 2025

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC

February 3rd 2025

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers

January 31st 2025

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.

BRAF V600E-Mutant Metastatic CRC Confers Poor Survival Outcomes Regardless of Synchronous vs Metachronous Status

January 30th 2025

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer

January 28th 2025

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.